SG&A Efficiency Analysis: Comparing AstraZeneca PLC and CRISPR Therapeutics AG

SG&A Efficiency: AstraZeneca vs. CRISPR Therapeutics

In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. AstraZeneca PLC, a global biopharmaceutical leader, and CRISPR Therapeutics AG, a pioneer in gene-editing technology, present a fascinating contrast in their SG&A spending from 2014 to 2023.

AstraZeneca's SG&A expenses have shown a steady increase, peaking in 2022 with a 90% rise from 2016. This reflects their expansive global operations and robust marketing strategies. In contrast, CRISPR Therapeutics, with its innovative focus, has seen a more modest increase, with expenses growing by approximately 1,900% over the same period, albeit from a much smaller base. This highlights their strategic investments in research and development.

This analysis underscores the differing strategies of established pharmaceutical giants and emerging biotech firms, offering insights into their operational priorities and market positioning.